Fendrix

Phase 3

Dynavax Technologies Corporation (DVAX)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in End Stage Renal Disease

RMTISoluble Ferric Pyrophosphate in liquid bicarbonate

Phase 2

View Full Landscape

Drug Information

Target Indication

End Stage Renal Disease

Clinical Trial

NCT01195246

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA2/2/2005

Fendrix

Fendrix is indicated in adolescents and adults from the age of 15 years onwards for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes for patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

DVAX

Dynavax Technologies Corporation

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

HEPLISAVPhase 3

Hepatitis B

Engerix-BPhase 3

Hepatitis B